ArticleAmerican journal of translational research2010
CD133, Trop-2 and alpha2beta1 integrin surface receptors as markers of putative human prostate cancer stem cells.
Article in American journal of translational research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 72 citations in OpenAlex.
- Canonical Wnt signaling in the regulation of prostate cancer stem cells: a key driver of castration-resistant prostate cancer and a therapeutic opportunity.Journal of translational medicine · 2026Review
- Unravelling therapeutic resistance: role of cancer stem cell and microRNA in metastatic prostate cancer.Frontiers in molecular biosciences · 2026Review
- TROP2 in colorectal carcinoma: associations with histopathology, molecular phenotype, and patient prognosis.The journal of pathology. Clinical research · 2024Article
- Tissue-specific cancer stem/progenitor cells: Therapeutic implications.World journal of stem cells · 2023Review
- State-of-the-art therapeutic strategies for targeting cancer stem cells in prostate cancer.Frontiers in oncology · 2023Review
- Prostate Cancer Stem Cells: The Role of CD133.Cancers · 2022Review
- Article
- Characterization of Immunogenicity of Malignant Cells with Stemness in Intrahepatic Cholangiocarcinoma by Single-Cell RNA Sequencing.Stem cells international · 2022Article
- Role of prostate cancer stem-like cells in the development of antiandrogen resistance.Cancer drug resistance (Alhambra, Calif.) · 2022Review
- Physical confinement during cancer cell migration triggers therapeutic resistance and cancer stem cell-like behavior.Cancer letters · 2021Article
- Recent technological advancements in stem cell research for targeted therapeutics.Drug delivery and translational research · 2020Review
- Molecular mechanisms of docetaxel resistance in prostate cancer.Cancer drug resistance (Alhambra, Calif.) · 2020Review
- Review
- Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer.Oncotarget · 2019Article
- Article
- Article
- TNF-α promotes colon cancer cell migration and invasion by upregulating TROP-2.Oncology letters · 2018Article
- Co-Expression of Putative Cancer Stem Cell Markers CD44 and CD133 in Prostate Carcinomas.Pathology oncology research : POR · 2017Article
- A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland.Cancers · 2017Review
- Cancer Stem Cell Gene Variants Predict Disease Recurrence in Patients Treated with Radical Prostatectomy for Prostate Cancer.International journal of medical sciences · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cancer stem cells (CSCs) play a key role in initiation and development of cancer and are attractive targets for therapy. The identification of CSC surface receptors to be used as therapeutic targets in vivo remains a difficult task. In this study, we assessed the expression pattern of three surface receptors: CD133, Trop-2 and alpha2beta1 integrin in human prostate cancer in order to identify CSC-niches. CD133 was found to be expressed in small clusters of cells localized in focal areas of benign as well as malignant lesions, suggesting that this protein is a bona fide marker of the prostate stem/progenitor compartment. Trop-2 was localized in both basal and luminal layers of benign glands and was highly expressed in malignant lesions. Moreover, isolated cells in benign and malignant areas were found to co-express both CD133 and Trop-2. alpha2beta1 integrin was expressed in the prostatic epithelium as well as in the surrounding stroma, limiting its utility as a marker of CSCs. In summary, we demonstrate that the combination of CD133 and Trop-2 is useful to mark putative CSC-containing compartments in human prostate.
Indexed as
Identifiers
20407603PMC2855629W1525789727What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.